{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-400144","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2026-09-24T11:15:56+00:00","discovered_at":"2026-09-24T11:35:04.076670+00:00","generated_at":"2026-09-24T11:35:35.543559+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Cullinan outlines Q4 2026 data readouts for CLN-978, velinotamig, CLN-049","bullets":["CLN-978 (CD19xCD3 TCE): multi-dose and single target dose data for SLE, RA, Sjögren's disease in December.","Velinotamig (BCMAxCD3 TCE): Genrix Bio Phase 1 SLE multi-dose data at ACR Convergence 2026 on Nov 8, 2026.","CLN-049 (FLT3xCD3 TCE): updated Phase 1 dose-escalation data in relapsed/refractory AML in December.","CEO notes successful FDA meeting for CLN-049; registrational Phase 2 study planned to initiate.","All data are from ongoing Phase 1 trials; no efficacy results disclosed yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-400144","json":"https://secwatch.observer/filing/0001193125-26-400144.json","markdown":"https://secwatch.observer/filing/0001193125-26-400144.md","text":"https://secwatch.observer/filing/0001193125-26-400144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526400144/0001193125-26-400144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526400144/cgem-20260924.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-24T11:35:35.543559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}